PTHS (channeltherapeutics.com) Future Price to Earnings

The investment potential of Channel Therapeutics (PTHS) is based on attracting top neurobiologists and providing them with a cutting-edge scientific foundation. The forward P/E ratio trend for the company on the GURU.Markets terminal linear chart confirms this, while the 0.00 metric reflects current dynamics. The foundation consists of expansion plans for small molecules to capture the neuropharmacology market and the adaptation of the clinical portfolio to meet new targets.

PTHS - Channel Therapeutics Inc. Projected Price to Earnings Ratio over the range 07/03/2025 - 11/12/2026

Financial and market metric breakdowns for Channel Pharma (PTHS)

- current price and projected stock value:

Stock Quotes Channel Therapeutics Corp|PTHS - Fair Value Consensus

- business market valuation indicators:

Market Value Channel Therapeutics Inc.|PTHS - Business Value

- balance sheet equity data:

Book Value per Share Channel Therapeutics|PTHS - Total Stockholders' Equity|Market Cap to Net Assets Ratio channeltherapeutics.com|PTHS - Company Total Assets

- business debt structure and liquidity details:

- earnings and market ratios statistics:

PTHS - Annual Net Income|Future Profit Channel Therapeutics|PTHS - Market Cap to Earnings|Forward P/E Multiple Channel|PTHS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Channel Therapeutics Inc.|PTHS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Channel Therapeutics|PTHS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months channeltherapeutics.com|PTHS - Earnings per share growth this year|Net earnings per share growth forecast for next year Channel Therapeutics

Analysis of all company metrics:PTHS Channel Therapeutics Corp

Signature product of Channel Therapeutics

The metric is calculated as the ratio of current market capitalization to projected earnings for the next twelve months, reflecting market expectations regarding future business efficiency. An analysis of the forward P/E NTM for Channel Therapeutics (PTHS) allows investors to filter out market noise and value the company's innovative molecules, accounting for the scaling of licensing revenues from strategic partners.

Competing companies